Author's posts
How a Duty To Spend Wisely on Worker Benefits Could Loosen PBMs’ Grip on Drug Prices
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” PBMs — or force them to change.
How Measles, Whooping Cough, and Worse Could Roar Back on RFK Jr.’s Watch
Inoculation campaigns that protect children and adults from dangerous diseases rely on a delicate web of state and federal laws and programs. If senior officials cast doubt on vaccine safety, the whole system might collapse, especially in red states.
Scientists Fear What’s Next for Public Health if RFK Jr. Is Allowed To ‘Go Wild’
As federal health scientists await an unprecedented takeover by medical skeptics in the second Trump administration, some are said to be preparing résumés or retirement papers.
Helene and CVS Land Double Whammy for 25,000 Patients Who Survive on IV Nutrition
A Massachusetts woman ended up stranded in the hospital because CVS stopped providing the IV nutrition she needs to survive at home. Without it, she’d starve.
Employers Haven’t a Clue How Their Drug Benefits Are Managed
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
FDA’s Promised Rules on Pulse Oximeters Unlikely To End Decades of Racial Bias
For decades, the pulse oximeters used in hospitals, ambulances, and homes have underestimated the oxygen needs of darker-skinned patients. The FDA is preparing guidelines to fix that. But will the new rules go far enough?
How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices
As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
The Chicken and Egg Problem of Fighting Another Flu Pandemic
The spread of an avian flu virus in cattle has again brought public health attention to the potential for a global pandemic. Fighting it would depend, for now, on 1940s technology that makes vaccines from hens’ eggs.
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
